Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenetic chemotherapy: initial experience.

PURPOSE To determine whether wide-volume perfusion computed tomography (CT) performed with a new generation scanner can allow evaluation of the effects of chemotherapy combined with antiangiogenetic treatment on the whole tumor mass in patients with locally advanced lung adenocarcinoma and to determine if changes in CT numbers correlate with the response to therapy as assessed by conventional response evaluation criteria in solid tumors (RECIST). MATERIALS AND METHODS Forty-five patients with unresectable lung adenocarcinoma underwent perfusion CT before and 40 and 90 days after chemotherapy and antiangiogenetic treatment. RECIST measurements and calculations of blood flow, blood volume, time to peak, and permeability were performed by two independent blinded radiologists. Pearson correlation coefficient was used to assess the correlation between baseline CT numbers. Baseline and follow-up perfusion parameters of the neoplastic lesions were tested overall for statistically significant differences by using the repeated-measures analysis of variance and then were also compared on the basis of the therapy response assessed according to the RECIST criteria. RESULTS Pearson correlation coefficient showed a significant correlation between baseline values of blood flow and blood volume (ρ = 0.48; P = .001), time to peak and permeability (ρ = 0.31; P = .04), time to peak and blood flow (ρ = -0.66; P < .001), and time to peak and blood volume (ρ = -0.39; P = .007). Blood flow, blood volume, and permeability values were higher in responding patients than in the other patients, with a significant difference at second follow-up for blood flow (P = .0001), blood volume (P = .02), and permeability (P = .0001); time to peak was higher in nonresponding patients (P = .012). CONCLUSION Perfusion CT imaging may allow evaluation of lung cancer angiogenesis demonstrating alterations in vascularity following treatment.

[1]  T. Vogl,et al.  Functional CT of squamous cell carcinoma in the head and neck: repeatability of tumor and muscle quantitative measurements, inter- and intra-observer agreement , 2008, European Radiology.

[2]  Jia-Yu Sun,et al.  Peripheral lung carcinoma: correlation of angiogenesis and first-pass perfusion parameters of 64-detector row CT. , 2008, Lung cancer.

[3]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[4]  Ernst Klotz,et al.  Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy. , 2009, Radiology.

[5]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[6]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[7]  V. Goh,et al.  Quantitative assessment of tissue perfusion using MDCT: comparison of colorectal cancer and skeletal muscle measurement reproducibility. , 2006, AJR. American journal of roentgenology.

[8]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[9]  Ernst Klotz,et al.  Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements. , 2006, Radiology.

[10]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[11]  L. Tanoue,et al.  Erlotinib in Previously Treated Non-Small-Cell Lung Cancer , 2007 .

[12]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[13]  S. Hill,et al.  Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumours. , 1995, British Journal of Cancer.

[14]  Ning Wu,et al.  Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. , 2009, AJR. American journal of roentgenology.

[15]  C. Angeletti,et al.  Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  Vicky Goh,et al.  Acute tumor vascular effects following fractionated radiotherapy in human lung cancer: In vivo whole tumor assessment using volumetric perfusion computed tomography. , 2007, International journal of radiation oncology, biology, physics.

[17]  M. Dewhirst,et al.  Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. , 1996, Cancer research.

[18]  Farida Cheriet,et al.  Large deformation registration of contrast-enhanced images with volume-preserving constraint , 2007, SPIE Medical Imaging.

[19]  Arzu Yorgancioglu,et al.  Thorax perfusion CT in non-small cell lung cancer , 2007, Comput. Medical Imaging Graph..

[20]  D. Sahani,et al.  Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. , 2005, Radiology.

[21]  H. Fichte,et al.  Quantitative assessment of lung cancer perfusion using MDCT: does measurement reproducibility improve with greater tumor volume coverage? , 2006, AJR. American journal of roentgenology.

[22]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[23]  Oleg S. Pianykh,et al.  Body tumor CT perfusion protocols: optimization of acquisition scan parameters in a rat tumor model. , 2009, Radiology.

[24]  S. Goldberg,et al.  CT perfusion for determination of pharmacologically mediated blood flow changes in an animal tumor model. , 2007, Radiology.

[25]  J. Drevs,et al.  The use of vascular biomarkers and imaging studies in the early clinical development of anti‐tumour agents targeting angiogenesis , 2006, Journal of internal medicine.

[26]  G. Scagliotti,et al.  Targeting Angiogenesis with Multitargeted Tyrosine Kinase Inhibitors in the Treatment of Non-Small Cell Lung Cancer , 2010, The oncologist.

[27]  Massimo Bellomi,et al.  CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. , 2007, Radiology.

[28]  Fabian Kiessling,et al.  Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization and treatment monitoring? , 2004, European Radiology.